These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23391543)

  • 41. [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
    Eckel F; Schmelz R; Adelsberger H; Erdmann J; Quasthoff S; Lersch C
    Dtsch Med Wochenschr; 2002 Jan; 127(3):78-82. PubMed ID: 11797144
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oxaliplatin-induced proximal renal tubular acidosis.
    Negro A; Grasselli C; Galli P
    Intern Emerg Med; 2010 Jun; 5(3):267-8. PubMed ID: 19937480
    [No Abstract]   [Full Text] [Related]  

  • 43. Severe anaphylactic reactions to oxaliplatin.
    Tournigand C; Maindrault-Goebel F; Louvet C; de Gramont A; Krulik M
    Eur J Cancer; 1998 Jul; 34(8):1297-8. PubMed ID: 9849497
    [No Abstract]   [Full Text] [Related]  

  • 44. Exenatide Facilitates Recovery from Oxaliplatin-Induced Peripheral Neuropathy in Rats.
    Fujita S; Ushio S; Ozawa N; Masuguchi K; Kawashiri T; Oishi R; Egashira N
    PLoS One; 2015; 10(11):e0141921. PubMed ID: 26536615
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New data question treatment for oxaliplatin neurotoxicity.
    Wolf SL
    Clin J Oncol Nurs; 2008 Feb; 12(1):14; author reply 14. PubMed ID: 18323035
    [No Abstract]   [Full Text] [Related]  

  • 46. Immunohemolytic anemia following oxaliplatin administration.
    Garufi C; Vaglio S; Brienza S; Conti L; D'Attino RM; Girelli G; Terzoli E
    Ann Oncol; 2000 Apr; 11(4):497. PubMed ID: 10847475
    [No Abstract]   [Full Text] [Related]  

  • 47. Oxaliplatin-associated neuropathy: a review.
    Cersosimo RJ
    Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
    Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
    Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An overview of chemotherapy-induced peripheral sensory neuropathy, focusing on oxaliplatin.
    Gent P; Massey K
    Int J Palliat Nurs; 2001 Jul; 7(7):354-9. PubMed ID: 11951404
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Efficacy and safety of pregabalin for oxaliplatin- and paclitaxel-induced peripheral neuropathy].
    Nihei S; Sato J; Kashiwaba M; Itabashi T; Kudo K; Takahashi K
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1189-93. PubMed ID: 24047777
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemotherapy-induced peripheral neuropathy: A need for standardization in measurement.
    Dunlap B; Paice JA
    J Support Oncol; 2006 Sep; 4(8):398-9. PubMed ID: 17004514
    [No Abstract]   [Full Text] [Related]  

  • 52. Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system.
    Binder A; Stengel M; Maag R; Wasner G; Schoch R; Moosig F; Schommer B; Baron R
    Eur J Cancer; 2007 Dec; 43(18):2658-63. PubMed ID: 17855072
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fatal oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report.
    Baretta Z; Falci C; Piva E; Conte P
    Clin Colorectal Cancer; 2013 Dec; 12(4):294-6. PubMed ID: 24188688
    [No Abstract]   [Full Text] [Related]  

  • 54. [Single nucleotide polymorphism analysis in the GSTP1 and ABCC2 genes about neuropathy by the Oxaliplatin].
    Mori Y; Katsumata K; Tsuchida A; Aoki T
    Gan To Kagaku Ryoho; 2008 Dec; 35(13):2377-81. PubMed ID: 19098406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and efficacy of calcium and magnesium infusions in the chemoprevention of oxaliplatin-induced sensory neuropathy in gastrointestinal cancers.
    Xu XT; Dai ZH; Xu Q; Qiao YQ; Gu Y; Nie F; Zhu MM; Tong JL; Ran ZH
    J Dig Dis; 2013 Jun; 14(6):288-98. PubMed ID: 23432969
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin.
    Tofthagen C; McAllister RD; McMillan SC
    Clin J Oncol Nurs; 2011 Apr; 15(2):182-8. PubMed ID: 21444285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy.
    Durand JP; Alexandre J; Guillevin L; Goldwasser F
    Anticancer Drugs; 2005 Jun; 16(5):587-91. PubMed ID: 15846125
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).
    Pachman DR; Qin R; Seisler DK; Smith EM; Beutler AS; Ta LE; Lafky JM; Wagner-Johnston ND; Ruddy KJ; Dakhil S; Staff NP; Grothey A; Loprinzi CL
    J Clin Oncol; 2015 Oct; 33(30):3416-22. PubMed ID: 26282635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
    Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
    Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Radiation recall with oxaliplatin: report of a case and a review of the literature.
    Chan RT; Au GK; Ho JW; Chu KW
    Clin Oncol (R Coll Radiol); 2001; 13(1):55-7. PubMed ID: 11292139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.